[Pain management: health economics and quality of life considerations].

abstract：:Lemborexant (DAYVIGO™) is an orally administered, dual orexin receptor (OXR) antagonist that exhibits reversible competitive antagonism at OXR1 and OXR2 (> affinity at OXR2) that was discovered and developed by Eisai Inc. for the treatment of adult patients with insomnia. In December 2019, lemborexant received its fir...

journal_title：Drugs

authors： Scott LJ

更新日期：2020-03-01 00:00:00

abstract：:Tipranavir is a non-peptidic HIV-1 protease inhibitor. It binds strongly and selectively, has a favourable resistance profile, and is administered orally twice daily with a subtherapeutic dosage of ritonavir in a 'boosted' regimen (TPV/r) in order to increase its bioavailability. Analysis of clinical isolates from tre...

journal_title：Drugs

authors： Croom KF,Keam SJ

更新日期：2005-01-01 00:00:00

abstract：:During depression, chronobiological disorders occur, such as disturbances in body temperature and early urinary excretion of a noradrenaline metabolite. Sleep patterns are disturbed in 90% of depressed patients; early REM sleep and shortened slow-wave sleep (stages 3 and 4), resulting in an increase in REM sleep, have...

journal_title：Drugs

authors： Rüther E

更新日期：1989-01-01 00:00:00

abstract：:Arrhythmia treatment has always been difficult, particularly as there are no good indicators of the optimal management strategy. The introduction of new antiarrhythmic agents has forced reappraisal of how these drugs are used. Dynamic electrocardiography and invasive electrophysiological studies are important tools fo...

journal_title：Drugs

authors： Campbell RW

更新日期：1988-11-01 00:00:00

abstract：:Liposomes are versatile drug carriers which can be used to solve problems of drug solubility, instability and rapid degradation. Both hydrophilic and hydrophobic drugs can be associated with liposomes and special techniques have been developed for the efficient loading of weak acids and weak bases into liposomes. Lipo...

journal_title：Drugs

authors： Allen TM

更新日期：1998-11-01 00:00:00

abstract：:The objective of this study was to evaluate the haemodynamic and antiarrhythmic effects of flecainide acetate in patients with heart failure. Flecainide acetate, a class Ic antiarrhythmic agent, was given intravenously to 9 patients with congestive heart failure and frequent ventricular arrhythmias with nonsustained v...

journal_title：Drugs

authors： Dunselman PH,Kingma JH,van Wijk LM,Dijk A,Wesseling H,Lie KI

更新日期：1985-01-01 00:00:00

abstract：:Drug-resistant tuberculosis (DR-TB) is an emerging global health threat as treatment involves complex multiple drug regimens, which are longer and more toxic than standard therapy and yet have worse outcomes. In the presence of resistance to one or more first-line drugs, an alternative regimen should be designed. A ma...

journal_title：Drugs

authors： Albanna AS,Menzies D

更新日期：2011-05-07 00:00:00

abstract：:Lanreotide Autogel (ATG) [Somatuline Depot] is a novel, long-acting preparation of the somatostatin analogue lanreotide acetate that acts via somatostatin receptors to reduce both growth hormone (GH) and insulin-like growth factor-I (IGF-I) levels. It is indicated for the management of acromegaly and, relative to most...

journal_title：Drugs

authors： Croxtall JD,Scott LJ

更新日期：2008-01-01 00:00:00

abstract：:Cisatracurium besilate (besylate) is a nondepolarising neuromuscular blocking agent with an intermediate duration of action. It is the R-cis, R'-cis isomer of atracurium besilate and is approximately 3-fold more potent than the mixture of isomers that constitute the parent drug. The ED95 for cisatracurium besilate (do...

journal_title：Drugs

authors： Bryson HM,Faulds D

更新日期：1997-05-01 00:00:00

abstract：:Four medicinal cancer biological blockbusters will end their patent lifespan by 2020. It is estimated that the total market for cancer biologicals will reach approximately US$68 billion at that time. Approximately 20 biosimilars have entered the European market since the launch of the original approval guidelines in 2...

journal_title：Drugs

authors： Camacho LH

更新日期：2017-06-01 00:00:00

abstract：:Miconazole is an imidazole antifungal drug which has recently become available for systemic use. Its antifungal activity has been well studied and it is active in vitro against a wide range of fungi. Published and unpublished reports of the use of miconazole in conditions such as systemic or mucocutaneous candidosis, ...

journal_title：Drugs

authors： Heel RC,Brogden RN,Pakes GE,Speight TM,Avery GS

更新日期：1980-01-01 00:00:00

abstract：:In a study of the effects of various NSAIDs on renal function in the elderly, indomethacin, tiaprofenic acid and sulindac were administered to patients ranging in age from 54 to 97 years for a period of 3 months. Indomethacin sustained release (25 mg tid) was administered to 66 patients, tiaprofenic acid (200 mg tid) ...

journal_title：Drugs

authors： Ishioka T

更新日期：1988-01-01 00:00:00

abstract：:A multicentre clinical trial was carried out to determine the activity and tolerability of ofloxacin in the treatment of lower respiratory tract infections. 667 patients were randomly allocated to 1 of 3 different twice daily dosage regimens: 400 mg (245 patients), 600 mg (211) or 800 mg (211). The mean duration of tr...

journal_title：Drugs

authors： Grassi C,Gialdroni Grassi G,Mangiarotti P

更新日期：1987-01-01 00:00:00

abstract：:Second-generation histamine H1 receptor antagonists (antihistamines) have been developed to reduce or eliminate the sedation and anticholinergic adverse effects that occur with older H1 receptor antagonists. This article evaluates second-generation antihistamines, including acrivastine, astemizole, azelastine, cetiriz...

journal_title：Drugs

authors： Slater JW,Zechnich AD,Haxby DG

更新日期：1999-01-01 00:00:00

abstract：:In a noncomparative trial, 73 adults with acute sinusitis confirmed by x-ray received cefixime 400mg once daily for approximately 10 days. At the end of treatment, 60 patients (82%) were cured, 2 (2.7%) had improved and 7 (9.6%) had failed therapy; 4 patients were not evaluable. No relapses were observed at follow-up....

journal_title：Drugs

authors： Gehanno P,Boucot I,Berche P,Uhlrich J

更新日期：1991-01-01 00:00:00

abstract：:A once-daily preservative-free fixed combination ophthalmic solution containing tafluprost 0.0015 % and timolol 0.5 % (hereafter referred to as tafluprost/timolol) [Taptiqom(®)] has been developed to lower intraocular pressure (IOP) whilst avoiding damage to the ocular surface associated with preservatives such as ben...

journal_title：Drugs

authors： Hoy SM

更新日期：2015-10-01 00:00:00

abstract：:Involuntary infertility is an increasing problem in this era of delayed childbearing. Fortunately, many advances have been made recently in the medical and surgical treatment of infertility. This article reviews the principal aetiologies of infertility and their treatments, and focuses on the current and future uses o...

journal_title：Drugs

authors： Quigley MM

更新日期：1986-08-01 00:00:00

abstract：:Bipolar disorder is a common and severe condition, and has a clinical outcome that is frequently sub-optimal. Only a small number of therapeutic options are currently available for the disorder. A growing range of novel therapeutic options for the treatment of bipolar disorder are under investigation. These include th...

journal_title：Drugs

authors： Berk M,Segal J,Janet L,Vorster M

更新日期：2001-01-01 00:00:00

abstract：:The discovery of immune inhibitory checkpoints has revolutionized the approach to the systemic treatment of cancer. The programmed death 1 (PD-1) inhibitory checkpoint, in particular, has played a key role in understanding how certain cancers can evade immune surveillance. Blocking the interaction between the PD-1 rec...

journal_title：Drugs

authors： Tsai KK,Daud AI

更新日期：2015-04-01 00:00:00

abstract：:Irinotecan (CPT-II) is a semisynthetic derivative of camptothecin. It and other camptothecin analogues/derivatives appear to exert their antitumour activity by binding to topoisomerase I. The active metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin (SN-38), has demonstrated potent growth inhibition of human col...

journal_title：Drugs

authors： Wiseman LR,Markham A

更新日期：1996-10-01 00:00:00

abstract：:Lumasiran (Oxlumo™) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1). By silencing the gene encoding glycolate oxidase, ...

journal_title：Drugs

authors： Scott LJ,Keam SJ

更新日期：2021-01-06 00:00:00

abstract：:Nizatidine is an H2-receptor antagonist which in animal studies was more active on a weight-for-weight basis than cimetidine in inhibiting basal and stimulated gastric acid secretion. Similarly, studies in humans have confirmed that nizatidine is a potent inhibitor of basal, nocturnal and stimulated gastric acid secre...

journal_title：Drugs

authors： Price AH,Brogden RN

更新日期：1988-11-01 00:00:00

abstract：:Pain is the main reason prompting patients to consult their physicians. In acute conditions, pain has a very particular significance as a warning sign, enabling the physician to attempt a diagnosis. Nevertheless, its detrimental effect upon the individual (even in the case of acute pain) and its cost to society are no...

journal_title：Drugs

authors： Brasseur L

更新日期：1997-01-01 00:00:00

abstract：:Immune checkpoint inhibition of programmed-death receptor 1 (PD-1) or its ligand (PD-L1) has become a standard in the treatment of metastatic non-small cell lung cancer, either as monotherapy or in combination. Recently, it could be shown that immunotherapy works as consolidation after chemoradiotherapy in locally adv...

journal_title：Drugs

authors： Heigener DF,Reck M

更新日期：2019-12-01 00:00:00

abstract：:Hepatitis E accounts for the major part of enterally transmitted non-A, non-B hepatitis worldwide. Its agent, the hepatitis E virus (HEV), is a small, single-stranded RNA virus. Only one serotype of HEV is recognised. Infection results in protective immunity with long-lived neutralising antibodies. In developing count...

journal_title：Drugs

authors： Worm HC,Wirnsberger G

更新日期：2004-01-01 00:00:00

abstract：:Gastric cancer is the seventh and oesophageal cancer the ninth most common cancer in the UK, and >50% of patients present with locally advanced or metastatic disease. The incidence of oesophageal and oesophagogastric junctional tumours is increasing, making these important disease entities to understand and research. ...

journal_title：Drugs

authors： Jackson C,Starling N,Chua YJ,Cunningham D

更新日期：2007-01-01 00:00:00

abstract：:Locally advanced prostate cancer (LAPC) is a heterogeneous entity usually embracing T3-4 and/or pelvic lymph-node-positive disease in the absence of established metastases. Outcomes for LAPC with single therapies have traditionally been poor, leading to the investigation of adjuvant therapies. Prostate cancer is a hor...

journal_title：Drugs

authors： Martin JM,Supiot S,Berthold DR

更新日期：2011-05-28 00:00:00

abstract：:Ovulation induction is the most common medical intervention for the treatment of infertility. Clomifene is generally the first treatment choice for patients with amenorrhoea, unless there is profound hypothalamic deficiency. When clomifene fails to induce ovulation, menotropins (human menopausal gonadotrophin) or gona...

journal_title：Drugs

authors： Collins JA,Hughes EG

更新日期：1995-09-01 00:00:00

abstract：:The development of thrombosis involves 4 main factors: the vessel wall, the formed elements of the blood, blood coagulation, and blood flow. In venous thrombosis, however, the major part in both the initiation and growth of thrombi is played by the platelets. In selecting drugs which inhibit platelet function it is he...

journal_title：Drugs

authors： Mustard JF,Packham MA

更新日期：1975-01-01 00:00:00

abstract：:Drug development offers potential solutions to a number of tropical health diseases, although the expense of pharmaceutical research and lack of return on investment has limited the production of new agents. The greatest successes have been through the development of single dose therapy and mass treatment control prog...

journal_title：Drugs

authors： Stephenson I,Wiselka M

更新日期：2000-11-01 00:00:00